EPHB6 and neoplasm: Our assessment of TCGA data for immunohistochemistry-based breast cancer subtype classification revealed that EPHB6 is also significantly downregulated in patient samples, representing very heterogeneous and aggressive tumours of the TNBC group (Figure 1C).